NEW YORK, April 18, 2023 /PRNewswire/ -- The autoinjectors market size is forecasted to increase by USD 134,014.58 million from 2022 to 2027, at a CAGR of 25.14%, according to the recent market study by Technavio. The growth of the market will be driven by the increasing prevalence of allergies and the need for immediate care, the gowing popularity of injectable therapies, and the rise in commercial approvals of new products. Technavio offers in-depth market insights that assist global businesses to obtain growth opportunities. Read a Sample Report
Autoinjectors market Vendor Analysis:
The global autoinjectors market is highly competitive, with several major players vying for market shares. The market is projected to continue growing, driven by factors such as the increasing prevalence of chronic diseases and the growing demand for the self-administration of drugs. Technavio has extensively analyzed 15 major vendors, including AbbVie Inc., Amgen Inc., Bayer AG, Becton Dickinson and Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Halozyme Therapeutics Inc., Johnson and Johnson Services Inc., Johnson Medtech LLC, medmix Ltd., Merck KGaA, Owen Mumford Ltd., Pfizer Inc., RAVIMED Sp. zoo, Recipharm AB, SHL Medical AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Ypsomed AG
To provide a deeper understanding of the competitive landscape, Technavio has profiled key players along with the study that categorizes the global market segmentation. Download the Sample
Vendor Offerings -
- AbbVie Inc.- The company offers autoinjectors, namely Adalimumab.
- Amgen Inc. - The company offers autoinjectors, namely AutoTouch reusable autoinjector with Enbrel Mini cartridge.
- Bayer AG - The company offers autoinjectors such as BETACONNECT autoinjector with BETASERON syringes.
Key Benefits for Industry Players & Stakeholders –
- The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
- It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
- The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
Expand operations in the future - To get requisite details, ask for a custom report.
Autoinjectors market - Market Segmentation:
This autoinjectors market report extensively covers market segmentation by application (anaphylaxis, multiple sclerosis, rheumatoid arthritis, and diabetes), end-user (hospitals and clinics, and self-administration), and geography (North America, Europe, Asia, and Rest of World (ROW)).
- The market share growth by the anaphylaxis segment will be significant for the market growth during the forecast period. The increasing prevalence of anaphylaxis and food allergies at a global level generates the highest revenue for the segment. For instance, according to the Centers for Disease Control and Prevention (CDC), around 8% of children in the US have food allergies. The intramuscular administration of epinephrine is effective for most treatments for anaphylaxis. It is the first line of treatment drugs. Hence, the availability in the market of auto-injectors that enable self-administration of anaphylaxis medications and vendor support in demonstrating the process of self-administration are expected to propel this segment.
The report comprises of various segments as well as analysis of the trends and factors that are playing a substantial role in the market. Download the Sample Report
Autoinjectors market - Market Dynamics:
Key Drivers:
- One of the major driving factors for the growth of the autoinjectors market is the increasing prevalence of allergies and the need for immediate care.
- The prevalence of allergies to food items, pollens, food additives, latex, and dust and the risk of contracting anaphylaxis caused by these factors are increasing worldwide.
- Allergies are the sixth leading cause of chronic illness in the US, with an annual expenditure of more than USD 18 billion, according to CDC.
- In North America, more than 50 million people are affected by allergies every year, and on average, 30%-35% of the global population is diagnosed with allergies annually. The high prevalence of anaphylaxis in the US leads to the high adoption of generic epinephrine autoinjectors, which can treat symptoms with a small dose of epinephrine.
- Hence, the increasing prevalence of allergies and the need for immediate care will boost the growth of the global autoinjectors market during the forecast period.
Major Trends:
- An emerging trend in autoinjectors market that is fueling the market growth is the strategic alliances between companies.
- With several acquisitions/partnerships aimed at expanding the business by offering new mineral cosmetics, strategic alliances in the global autoinjector market are on the rise.
- For instance, Pfizer Inc. works in association with Antares Pharma to develop an autoinjector pen for an undisclosed Pfizer drug. These drugs utilize Antares Pharma patented QuickShot autoinjector and an unrevealed drug.
- Moreover, such strategic alliances will help Pfizer Inc. increase the potential number of products utilizing Antares Pharma's innovative QuickShot autoinjector technology platform.
- Hence, an increase in strategic alliances is expected to boost the growth of the global autoinjectors market during the forecast period.
Key Challenges:
- A major challenge in the autoinjectors market that is expected to impede market growth is the side-effects of autoinjectors.
- The side effects include infections, high and low blood pressure, muscle pain, headache, and diarrhea. Chemotherapy-induced anemia patients show side effects such as an increased incidence of fatigue, edema, nausea, vomiting, fever, and hypertension.
- Moreover, MS patients administered with autoinjectors are vulnerable to severe hepatic injury, including cases of hepatic failure.
- In certain cases, interferon beta-1 b-filled autoinjectors for such patients can also cause anaphylaxis.
- Hence, the associated side effects can impact the adoption of autoinjectors and encourage patients to opt for alternatives with less severe side effects
- Therefore, the side effects of autoinjectors are expected to slow down the growth of the global autoinjectors market during the forecast period.
In addition to the forecast, the report also highlights the key opportunities by analyzing drivers, trends, challenges for the market, buy the report
What are the key data covered in this Autoinjectors Market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the autoinjectors market between 2023 and 2027
- Precise estimation of the size of the autoinjectors market and its contribution to the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the autoinjectors market across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of autoinjectors market vendors
Gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Related Reports:
The high pressure contrast media injectors market size should rise by USD 113.21 million from 2022 to 2026 at a CAGR of 12.32%. Furthermore, this report extensively covers market segmentation by end-user (hospitals, diagnostics centers, and ambulatory surgical centers) and geography (North America, Europe, Asia, and ROW). The rising prevalence of CVD diseases is notably driving the high pressure contrast media injectors market growth.
The contrast injectors market size is expected to increase by USD 578.41 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 5%. Furthermore, this report extensively covers market segmentation by product (consumables and contrast injectors) and geography (North America, Europe, Asia, and ROW). A key factor driving growth in the contrast injectors market is the increasing prevalence of diseases and related risk factors.
Autoinjectors Market Scope |
|
Report Coverage |
Details |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 25.14% |
Market growth 2023-2027 |
USD 134,014.58 million |
Market structure |
Fragmented |
YoY growth 2022-2023 (%) |
24.1 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Amgen Inc., Bayer AG, Becton Dickinson and Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Halozyme Therapeutics Inc., Johnson and Johnson Services Inc., Johnson Medtech LLC, medmix Ltd., Merck KGaA, Owen Mumford Ltd., Pfizer Inc., RAVIMED Sp. zoo, Recipharm AB, SHL Medical AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Ypsomed AG |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse for Technavio's Health Care Reports
Table Of Contents :
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
- Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global autoinjectors market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global autoinjectors market 2017 - 2021 ($ million)
- 4.2 Application Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Application Segment 2017 - 2021 ($ million)
- 4.3 End-user Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – End-user Segment 2017 - 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Application
- 6.1 Market segments
- Exhibit 30: Chart on Application - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Application - Market share 2022-2027 (%)
- 6.2 Comparison by Application
- Exhibit 32: Chart on Comparison by Application
- Exhibit 33: Data Table on Comparison by Application
- 6.3 Anaphylaxis - Market size and forecast 2022-2027
- Exhibit 34: Chart on Anaphylaxis - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Anaphylaxis - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Anaphylaxis - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Anaphylaxis - Year-over-year growth 2022-2027 (%)
- 6.4 Multiple sclerosis - Market size and forecast 2022-2027
- Exhibit 38: Chart on Multiple sclerosis - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Multiple sclerosis - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Multiple sclerosis - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Multiple sclerosis - Year-over-year growth 2022-2027 (%)
- 6.5 Rheumatoid arthritis - Market size and forecast 2022-2027
- Exhibit 42: Chart on Rheumatoid arthritis - Market size and forecast 2022-2027 ($ million)
- Exhibit 43: Data Table on Rheumatoid arthritis - Market size and forecast 2022-2027 ($ million)
- Exhibit 44: Chart on Rheumatoid arthritis - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Rheumatoid arthritis - Year-over-year growth 2022-2027 (%)
- 6.6 Diabetes - Market size and forecast 2022-2027
- Exhibit 46: Chart on Diabetes - Market size and forecast 2022-2027 ($ million)
- Exhibit 47: Data Table on Diabetes - Market size and forecast 2022-2027 ($ million)
- Exhibit 48: Chart on Diabetes - Year-over-year growth 2022-2027 (%)
- Exhibit 49: Data Table on Diabetes - Year-over-year growth 2022-2027 (%)
- 6.7 Market opportunity by Application
- Exhibit 50: Market opportunity by Application ($ million)
- Exhibit 51: Data Table on Market opportunity by Application ($ million)
7 Market Segmentation by End-user
- 7.1 Market segments
- Exhibit 52: Chart on End-user - Market share 2022-2027 (%)
- Exhibit 53: Data Table on End-user - Market share 2022-2027 (%)
- 7.2 Comparison by End-user
- Exhibit 54: Chart on Comparison by End-user
- Exhibit 55: Data Table on Comparison by End-user
- 7.3 Hospitals and clinics - Market size and forecast 2022-2027
- Exhibit 56: Chart on Hospitals and clinics - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Data Table on Hospitals and clinics - Market size and forecast 2022-2027 ($ million)
- Exhibit 58: Chart on Hospitals and clinics - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Hospitals and clinics - Year-over-year growth 2022-2027 (%)
- 7.4 Self-administration - Market size and forecast 2022-2027
- Exhibit 60: Chart on Self-administration - Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Data Table on Self-administration - Market size and forecast 2022-2027 ($ million)
- Exhibit 62: Chart on Self-administration - Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Self-administration - Year-over-year growth 2022-2027 (%)
- 7.5 Market opportunity by End-user
- Exhibit 64: Market opportunity by End-user ($ million)
- Exhibit 65: Data Table on Market opportunity by End-user ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2022-2027 (%)
- Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2022-2027
- Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
- 9.4 Europe - Market size and forecast 2022-2027
- Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
- 9.5 Asia - Market size and forecast 2022-2027
- Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8 UK - Market size and forecast 2022-2027
- Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)
- 9.9 Germany - Market size and forecast 2022-2027
- Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
- 9.10 Canada - Market size and forecast 2022-2027
- Exhibit 99: Chart on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 100: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
- Exhibit 101: Chart on Canada - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on Canada - Year-over-year growth 2022-2027 (%)
- 9.11 China - Market size and forecast 2022-2027
- Exhibit 103: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 104: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 105: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on China - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ million)
- Exhibit 108: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 112: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 113: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification
- 12.3 AbbVie Inc.
- Exhibit 115: AbbVie Inc. - Overview
- Exhibit 116: AbbVie Inc. - Product / Service
- Exhibit 117: AbbVie Inc. - Key news
- Exhibit 118: AbbVie Inc. - Key offerings
- 12.4 Amgen Inc.
- Exhibit 119: Amgen Inc. - Overview
- Exhibit 120: Amgen Inc. - Product / Service
- Exhibit 121: Amgen Inc. - Key offerings
- 12.5 Bayer AG
- Exhibit 122: Bayer AG - Overview
- Exhibit 123: Bayer AG - Business segments
- Exhibit 124: Bayer AG - Key news
- Exhibit 125: Bayer AG - Key offerings
- Exhibit 126: Bayer AG - Segment focus
- 12.6 Becton Dickinson and Co.
- Exhibit 127: Becton Dickinson and Co. - Overview
- Exhibit 128: Becton Dickinson and Co. - Business segments
- Exhibit 129: Becton Dickinson and Co. - Key news
- Exhibit 130: Becton Dickinson and Co. - Key offerings
- Exhibit 131: Becton Dickinson and Co. - Segment focus
- 12.7 Eli Lilly and Co.
- Exhibit 132: Eli Lilly and Co. - Overview
- Exhibit 133: Eli Lilly and Co. - Product / Service
- Exhibit 134: Eli Lilly and Co. - Key offerings
- 12.8 F. Hoffmann La Roche Ltd.
- Exhibit 135: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 136: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 137: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 138: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 139: F. Hoffmann La Roche Ltd. - Segment focus
- 12.9 GlaxoSmithKline Plc
- Exhibit 140: GlaxoSmithKline Plc - Overview
- Exhibit 141: GlaxoSmithKline Plc - Business segments
- Exhibit 142: GlaxoSmithKline Plc - Key news
- Exhibit 143: GlaxoSmithKline Plc - Key offerings
- Exhibit 144: GlaxoSmithKline Plc - Segment focus
- 12.10 Halozyme Therapeutics Inc.
- Exhibit 145: Halozyme Therapeutics Inc. - Overview
- Exhibit 146: Halozyme Therapeutics Inc. - Product / Service
- Exhibit 147: Halozyme Therapeutics Inc. - Key offerings
- 12.11 Merck KGaA
- Exhibit 148: Merck KGaA - Overview
- Exhibit 149: Merck KGaA - Business segments
- Exhibit 150: Merck KGaA - Key news
- Exhibit 151: Merck KGaA - Key offerings
- Exhibit 152: Merck KGaA - Segment focus
- 12.12 Owen Mumford Ltd.
- Exhibit 153: Owen Mumford Ltd. - Overview
- Exhibit 154: Owen Mumford Ltd. - Product / Service
- Exhibit 155: Owen Mumford Ltd. - Key offerings
- 12.13 Pfizer Inc.
- Exhibit 156: Pfizer Inc. - Overview
- Exhibit 157: Pfizer Inc. - Product / Service
- Exhibit 158: Pfizer Inc. - Key news
- Exhibit 159: Pfizer Inc. - Key offerings
- 12.14 Recipharm AB
- Exhibit 160: Recipharm AB - Overview
- Exhibit 161: Recipharm AB - Business segments
- Exhibit 162: Recipharm AB - Key offerings
- Exhibit 163: Recipharm AB - Segment focus
- 12.15 Teva Pharmaceutical Industries Ltd.
- Exhibit 164: Teva Pharmaceutical Industries Ltd. - Overview
- Exhibit 165: Teva Pharmaceutical Industries Ltd. - Business segments
- Exhibit 166: Teva Pharmaceutical Industries Ltd. - Key news
- Exhibit 167: Teva Pharmaceutical Industries Ltd. - Key offerings
- Exhibit 168: Teva Pharmaceutical Industries Ltd. - Segment focus
- 12.16 Viatris Inc.
- Exhibit 169: Viatris Inc. - Overview
- Exhibit 170: Viatris Inc. - Business segments
- Exhibit 171: Viatris Inc. - Key offerings
- Exhibit 172: Viatris Inc. - Segment focus
- 12.17 Ypsomed AG
- Exhibit 173: Ypsomed AG - Overview
- Exhibit 174: Ypsomed AG - Business segments
- Exhibit 175: Ypsomed AG - Key offerings
- Exhibit 176: Ypsomed AG - Segment focus
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 177: Inclusions checklist
- Exhibit 178: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 179: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 180: Research methodology
- Exhibit 181: Validation techniques employed for market sizing
- Exhibit 182: Information sources
- 13.5 List of abbreviations
- Exhibit 183: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article